Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Sep;119(1):116-25.
doi: 10.1111/j.1365-2567.2006.02413.x. Epub 2006 Jun 22.

The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner

Affiliations

The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner

Gillian A Lang et al. Immunology. 2006 Sep.

Abstract

Specific interaction of class II/peptide with the T-cell receptor (TCR) expressed by class II-restricted CD4+ T helper (Th) cells is essential for in vivo production of antibodies reactive with T-dependent antigen. In response to stimulation with CD1d-binding glycolipid, Valpha14+ TCR-expressing, CD1d-restricted natural killer T (NKT) cells may provide additional help for antibody production. We tested the hypothesis that the CD1d-binding glycolipid alpha-galactosylceramide (alpha-GC) enhances production of antibodies reactive with T-dependent antigen in vivo. alpha-GC enhanced antibody production in vivo in a CD1d-dependent manner in the presence of class II-restricted Th cells and induced a limited antibody response in Th-deficient mice. alpha-GC also led to alterations in isotype switch, selectively increasing production of immunoglobulin G2b. Further analysis revealed that alpha-GC led to priming of class II-restricted Th cells in vivo. Additionally, we observed that alpha-GC enhanced production of antibodies reactive with T-independent antigen, showing the effects of NKT cells on B cells independently of Th cells. Our data show that NKT cells have multiple effects on the induction of a humoral immune response. We propose that NKT cells could be exploited for the development of novel vaccines where protective antibody is required.

PubMed Disclaimer

Figures

Figure 1
Figure 1
α-GC enhances T-dependent antibody production in a CD1d-dependent manner. (a) Splenocytes were harvested from C57BL/6 and CD1d−/− mice and analysed for binding of CD1d tetramer versus TCR-β (top row). Whole blood cells were analysed for CD1d (middle row) and class II expression (bottom row). (b) Mice were pre-bled (naive) and immunized s.c. with 400 μg OVA before obtaining immune primary and secondary bleed sera on days 14 and 28, respectively. Data show the end-point anti-OVA IgG1 titre in C57BL/6 and CD1−/− mice. Each data point represents an individual mouse for four mice per group. (c) Pre-bleed sera (naive) were obtained from C57BL/6 mice followed by s.c. immunization with α-GC alone (4 μg), OVA alone (5, 50, or 500 μg) or OVA mixed with α-GC. Immune sera were then obtained at day 14 post-immunization. CD1d−/− mice were treated, bled, and then immunized with 5 µg OVA either alone or mixed with α-GC, before obtaining immune sera at day 14. Data show mean ±SD end-point anti-OVA IgG1 titres for four mice per group. Statistically significant differences, as determined by Student's t-test, are indicated. Flow cytometry data in (a) are representative of at least six experiments. Data in (b) and (c) are representative of four similar experiments.
Figure 2
Figure 2
α-GC enhances anti-KLH titres in a CD1d/NKT-dependent manner. C57BL/6 and CD1d−/− mice were immunized s.c. with 10 μg KLH, 4 μg α-GC or KLH plus α-GC. On day 14, sera were obtained and anti-KLH IgG1 titres were assessed by ELISA. Data show the mean end-point titre ±SD for four mice per group and are representative of three similar experiments.
Figure 3
Figure 3
CD40-ligation following α-GC stimulation induces specific T-dependent antibody production in class II−/− mice. (a) Shows: CD1d tetramer binding (left panel); CD1d expression (middle); and class II expression (right) in class II−/− mice. (b) Mice were immunized s.c. on days 0, 7 and 14 with 400 μg OVA + 4 μg α-GC, OVA + α-GC then 100 μg rat IgG, OVA + α-GC + 100 μg anti-CD40, anti-CD40 alone, or OVA then anti-CD40. Anti-IgG ELISAS were performed on sera collected on days 0, 14 and 28. Data show the mean ± SD end-point titre for seven mice per group. Four out of seven mice were responsive in the OVA/α-GC/anti-CD40 group (the data from the three non-responsive mice are not shown). (c) Sera from the four responding OVA/α-GC/anti-CD40 immunized mice were tested for the presence of anti-HEL-specific IgG. Results from positive control sera (C57BL/6 mouse injected with HEL) are shown.
Figure 4
Figure 4
α-GC enhances the priming of Th cells. Pre-bleed sera (naive) were obtained from C57BL/6 mice followed by s.c. immunization with OVA alone (20 μg) or OVA plus α-GC (4 μg). Mice were bled (immune primary) then challenged s.c. with 20 μg NIP-conjugated OVA on day 14. On day 28, mice were bled (immune). (a) Anti-NIP-ELISAs were performed on day 28 sera. (b) Anti-OVA ELISAs were performed on day 14 sera. Data shows mean end-point antibody titre ± SD for four mice per group. Statistically significant differences are indicated.
Figure 5
Figure 5
α-GC enhances antibody responses to T-independent antigen. C57BL/6 and CD1d−/− mice were bled (naive) then immunized i.p. with 5 μg NP–Ficoll or NP–Ficoll plus 4 μg α-GC. On day 7, mice were bled (immune). ELISAs were then performed to assess anti-NP IgM, IgG1, IgG2b, IgG3, IgA and IgE titres in sera. Data show the mean end-point anti-NP titre ± SD for four mice per group. Statistically significant differences are indicated.

References

    1. Jung S, Unutmaz D, Wong P, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity. 2002;17:211–20. - PMC - PubMed
    1. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol. 2005;23:487–513. - PubMed
    1. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998;8:363–72. - PubMed
    1. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol. 1990;8:773–93. - PubMed
    1. Madsen L, Labrecque N, Engberg J, et al. Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci USA. 1999;96:10338–43. - PMC - PubMed

Publication types

MeSH terms